{"id":"pertuzumab-p","safety":{"commonSideEffects":[{"rate":"~20-25%","effect":"Diarrhea"},{"rate":"~15-20%","effect":"Nausea"},{"rate":"~10-15%","effect":"Fatigue"},{"rate":"~5-10%","effect":"Rash"},{"rate":"~5-10%","effect":"Vomiting"},{"rate":"~2-5%","effect":"Left ventricular dysfunction"}]},"_chembl":null,"_dailymed":{"setId":"17f85d17-ab71-4f5b-9fe3-0b8c822f69ff","title":"PERJETA (PERTUZUMAB) INJECTION, SOLUTION, CONCENTRATE [GENENTECH, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pertuzumab binds to the extracellular dimerization interface of HER2, distinct from the trastuzumab binding site. By preventing HER2 from forming heterodimers with HER3 and other HER family members, it blocks downstream signaling pathways critical for HER2-driven cancer cell proliferation and survival. This complementary mechanism to trastuzumab allows for synergistic activity when used in combination.","oneSentence":"Pertuzumab is a monoclonal antibody that blocks HER2 dimerization, preventing HER2 from pairing with other HER receptors and inhibiting tumor cell growth signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:08.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)"},{"name":"HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)"}]},"trialDetails":[{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT07340398","phase":"PHASE2","title":"Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12-25","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT07239271","phase":"PHASE3","title":"A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-16","conditions":"Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy","enrollment":2000},{"nctId":"NCT05704829","phase":"PHASE2","title":"NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West German Study Group","startDate":"2024-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":402},{"nctId":"NCT06754059","phase":"","title":"Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC","status":"RECRUITING","sponsor":"zhangjie","startDate":"2021-06-01","conditions":"HER2-positive Breast Cancer","enrollment":60},{"nctId":"NCT04675827","phase":"PHASE2","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2022-01-17","conditions":"HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer","enrollment":139},{"nctId":"NCT06435104","phase":"PHASE2","title":"Aromatherapy in the Treatment of Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-07","conditions":"Early Breast Cancer","enrollment":30},{"nctId":"NCT03595592","phase":"PHASE3","title":"Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Michelangelo","startDate":"2018-09-07","conditions":"Invasive Breast Cancer","enrollment":650},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT03674112","phase":"PHASE2","title":"A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-12-19","conditions":"HER2-Positive Early Breast Cancer","enrollment":160},{"nctId":"NCT05978648","phase":"PHASE2","title":"Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy","status":"RECRUITING","sponsor":"wang shusen","startDate":"2023-09-20","conditions":"Breast Neoplasms","enrollment":116},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT05430347","phase":"PHASE2","title":"Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-04-15","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT04395508","phase":"","title":"An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic","status":"APPROVED_FOR_MARKETING","sponsor":"Genentech, Inc.","startDate":"","conditions":"HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT04293796","phase":"NA","title":"Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2019-10-08","conditions":"Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB","enrollment":60},{"nctId":"NCT02000596","phase":"PHASE2","title":"1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2014-01","conditions":"Metastatic Breast Cancer","enrollment":2},{"nctId":"NCT05346107","phase":"PHASE2","title":"PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2020-01-01","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":100},{"nctId":"NCT05255523","phase":"PHASE2","title":"Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University Union Hospital","startDate":"2022-02-20","conditions":"Advanced Breast Cancer","enrollment":60},{"nctId":"NCT03238495","phase":"PHASE2","title":"Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer","status":"UNKNOWN","sponsor":"Qamar Khan","startDate":"2017-08-15","conditions":"HER2-positive Breast Cancer","enrollment":100},{"nctId":"NCT04717531","phase":"PHASE2","title":"Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-06-03","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT02379585","phase":"PHASE1, PHASE2","title":"Fasting on Newly Diagnosed Breast Cancer","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2013-01","conditions":"HER2-positive Breast Cancer","enrollment":8},{"nctId":"NCT02345772","phase":"PHASE1, PHASE2","title":"Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2014-07","conditions":"HER2-positive Breast Cancer, ER-positive Breast Cancer","enrollment":4},{"nctId":"NCT00976989","phase":"PHASE2","title":"A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-11","conditions":"Breast Cancer","enrollment":225}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":504,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["patuozhudankang"],"phase":"marketed","status":"active","brandName":"pertuzumab (P)","genericName":"pertuzumab (P)","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pertuzumab is a monoclonal antibody that blocks HER2 dimerization, preventing HER2 from pairing with other HER receptors and inhibiting tumor cell growth signaling. Used for HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy), HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}